EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non-ionotropic signaling through the NMDA receptor GluN2B carboxy-terminal domain drives dendritic spine plasticity and reverses fragile X phenotypes

Stephanie A Barnes, Aurore Thomazeau, Peter S B Finnie, Maxwell J Heinrich, Arnold J Heynen, Noburu H Komiyama, Seth G N Grant, Frank S Menniti, Emily K Osterweil, Mark F Bear

Cell Reports · 2025

DOI: 10.1016/j.celrep.2025.115311 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Stephanie A Barnes und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Centre for Discovery Brain Sciences, …. Hauptthemen laut MEDLINE: Receptors, N-Methyl-D-Aspartate, Dendritic Spines, Fragile X Syndrome, Neuronal Plasticity. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NICHD NIH HHS, National Institute of Mental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N-methyl-D-aspartate (NMDA)-induced spine shrinkage proceeds independently of ion flux and requires the initiation of de novo protein synthesis. Using subtype-selective pharmacological and genetic tools, we find that structural plasticity is dependent on ligand binding to GluN2B-containing NMDA receptors (NMDARs) and signaling via the GluN2B carboxy-terminal domain (CTD). Disruption of non-ionotropic signaling by replacing the GluN2B CTD with the GluN2A CTD leads to an increase in spine density, dysregulated basal protein synthesis, exaggerated long-term depression mediated by G-protein-coupled metabotropic glutamate receptors (mGluR-LTD), and epileptiform activity reminiscent of phenotypes observed in the Fmr1 knockout (KO) model of fragile X syndrome. By crossing the Fmr1 KO mice with animals in which the GluN2A CTD has been replaced with the GluN2B CTD, we observe a correction of these core fragile X phenotypes. These findings suggest that non-ionotropic NMDAR signaling through GluN2B may represent a novel therapeutic target for the treatment of fragile X and related causes of intellectual disability and autism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, N-Methyl-D-AspartateDendritic SpinesFragile X SyndromeNeuronal PlasticitySignal TransductionAnimalsFragile X Messenger Ribonucleoprotein 1PhenotypeMiceMice, KnockoutMaleProtein DomainsMice, Inbred C57BLLong-Term Synaptic DepressionReceptors, Metabotropic Glutamate

Stichwörter der Autor:innen

AGSCP: NeuroscienceFXSGlyx-13LTDNMDARaudiogenic seizuresdendritic spinesepileptogenesisfragile X syndromelong-term depressionmGluR5non-ionotropic

Substanzen

Receptors, N-Methyl-D-AspartateFragile X Messenger Ribonucleoprotein 1Receptors, Metabotropic GlutamateNR2B NMDA receptorFmr1 protein, mouse

Autor:innen und Institutionen

  • The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburg…
  • The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK; Simons Initiative for the Developing Brain (SIDB), Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK…
  • Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK; Simons Initiative for the Developing Brain (SIDB), Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK.
  • MindImmune Therapeutics, Inc., The George & Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI 02881, USA.
  • Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK; F.M. Kirby Center for Neurobiology, Translational Neuroscience Center, Department of Neurology, H…

Förderung

  • NINDS NIH HHS
  • NICHD NIH HHS
  • National Institute of Mental Health
  • FRAXA Research Foundation
  • National Institutes of Health

Zitieren

APA

Barnes, S. A., Thomazeau, A., Finnie, P. S. B., Heinrich, M. J., Heynen, A. J., Komiyama, N. H., Grant, S. G. N., Menniti, F. S., Osterweil, E. K., & Bear, M. F. (2025). Non-ionotropic signaling through the NMDA receptor GluN2B carboxy-terminal domain drives dendritic spine plasticity and reverses fragile X phenotypes. Cell Reports. https://doi.org/10.1016/j.celrep.2025.115311

Vancouver

Barnes SA, Thomazeau A, Finnie PSB, Heinrich MJ, Heynen AJ, Komiyama NH, et al. Non-ionotropic signaling through the NMDA receptor GluN2B carboxy-terminal domain drives dendritic spine plasticity and reverses fragile X phenotypes. Cell Reports. 2025. doi:10.1016/j.celrep.2025.115311

BibTeX
@article{Barnes2025,
  author = {Barnes, Stephanie A and Thomazeau, Aurore and Finnie, Peter S B and Heinrich, Maxwell J and Heynen, Arnold J and Komiyama, Noburu H and Grant, Seth G N and Menniti, Frank S and Osterweil, Emily K and Bear, Mark F},
  title = {Non-ionotropic signaling through the NMDA receptor GluN2B carboxy-terminal domain drives dendritic spine plasticity and reverses fragile X phenotypes},
  journal = {Cell Reports},
  year = {2025},
  doi = {10.1016/j.celrep.2025.115311}
}
Kostenlos starten →